Search
Selpercatinib
go.drugbank.com/drugs/DB15685ApprovedInvestigationalSelpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although mult...
Lotilaner
go.drugbank.com/drugs/DB17992ApprovedInvestigationalVet approved[A260746, L47556] Lotilaner consists of two enantiomers: the S-enantiomer is active _in vivo_, while the R-enantiomer is reported to exhibit low biological activity. … [L47546] Lotilaner has largely been used for veterinary uses as an antiparasitic agent to treat flea and tick infestations in animals.
Doxofylline
go.drugbank.com/drugs/DB09273InvestigationalDecreased affinity for adenosine receptors may account for the better safety profile of doxofylline compared to theophylline [L1169]. … In contrast with other xanthine derivatives, doxofylline does not significantly bind to adenosine alpha-1 or alpha-2 receptors and lacks stimulating effects.
Chloroquine
go.drugbank.com/drugs/DB00608ApprovedInvestigationalVet approved[A191655] It was the drug of choice to treat malaria until the development of newer antimalarials such as [pyrimethamine], [artemisinin], and [mefloquine].
Vayarin
go.drugbank.com/drugs/DB09328ApprovedApproximately 60% of the users who completed 12 weeks of therapy reported subjective benefits from treatment. … Vayarin is a novel therapy for ADHD that appears to be effective in several studies [L1501, L1502, L1503].
Brimonidine
go.drugbank.com/drugs/DB00484ApprovedInvestigational[A178945] Thus brimonidine is an effective and safe alternative to beta-blockers, in patients with, or at high risk for, cardiopulmonary disease. … Because it is oxidately stable, brimonidine is associated with fewer reports of ocular allergic reactions compared to other alpha-2 adrenergic agonists.
Products: ALPHAGAN P OPHTHALMIC SOLUTION 0.15% w/v, Corneax, eye drops solution 0.2% w/vProtein C
go.drugbank.com/drugs/DB11312ApprovedInvestigationalIt is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC). … A lack of protein C in the body would lead to unchecked coagulation activation, resulting in thrombin generation and intravascular clot formation.
Apixaban
go.drugbank.com/drugs/DB06605ApprovedInvestigationalApixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. ...
Donepezil
go.drugbank.com/drugs/DB00843ApprovedInvestigationalIn 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. … Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia.
Products: DONEPEZIL ARROW GENERICS, DONEPEZIL DOC GENERICICresol
go.drugbank.com/drugs/DB11143ApprovedIngestion of cresol induces toxicity in humans and can lead to burning of the mouth and throat, abdominal pain, and/or vomiting. … At concentrations normally found in the environment however, cresols do not pose any significant risk for the general population.